Poland
· Delayed Price · Currency is PLN Genomtec Statistics
Total Valuation
Genomtec has a market cap or net worth of PLN 99.67 million. The enterprise value is 88.16 million.
| Market Cap | 99.67M |
| Enterprise Value | 88.16M |
Important Dates
The next estimated earnings date is Friday, November 29, 2024.
| Earnings Date | Nov 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Genomtec has 13.32 million shares outstanding. The number of shares has increased by 15.02% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 13.32M |
| Shares Change (YoY) | +15.02% |
| Shares Change (QoQ) | +17.40% |
| Owned by Insiders (%) | 10.17% |
| Owned by Institutions (%) | 5.56% |
| Float | 10.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 7.81 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.02 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -15.70 |
Financial Position
The company has a current ratio of 2.06, with a Debt / Equity ratio of 0.20.
| Current Ratio | 2.06 |
| Quick Ratio | 1.99 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.45 |
| Interest Coverage | -100.72 |
Financial Efficiency
Return on equity (ROE) is -84.64% and return on invested capital (ROIC) is -44.17%.
| Return on Equity (ROE) | -84.64% |
| Return on Assets (ROA) | -29.21% |
| Return on Capital (ROIC) | -44.17% |
| Revenue Per Employee | 118 |
| Profits Per Employee | -646,882 |
| Employee Count | 17 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.83% in the last 52 weeks. The beta is 0.27, so Genomtec's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -30.83% |
| 50-Day Moving Average | 7.81 |
| 200-Day Moving Average | 10.09 |
| Relative Strength Index (RSI) | 38.81 |
| Average Volume (20 Days) | 11,970 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genomtec had revenue of PLN 2,000 and -11.00 million in losses. Loss per share was -0.85.
| Revenue | 2,000 |
| Gross Profit | -2.28M |
| Operating Income | -10.88M |
| Pretax Income | -11.05M |
| Net Income | -11.00M |
| EBITDA | -8.88M |
| EBIT | -10.88M |
| Loss Per Share | -0.85 |
Balance Sheet
The company has 14.06 million in cash and 2.55 million in debt, giving a net cash position of 11.51 million or 0.86 per share.
| Cash & Cash Equivalents | 14.06M |
| Total Debt | 2.55M |
| Net Cash | 11.51M |
| Net Cash Per Share | 0.86 |
| Equity (Book Value) | 12.77M |
| Book Value Per Share | 0.96 |
| Working Capital | 8.16M |
Cash Flow
In the last 12 months, operating cash flow was -4.63 million and capital expenditures -991,000, giving a free cash flow of -5.62 million.
| Operating Cash Flow | -4.63M |
| Capital Expenditures | -991,000 |
| Free Cash Flow | -5.62M |
| FCF Per Share | -0.42 |
Margins
| Gross Margin | n/a |
| Operating Margin | -543,900.00% |
| Pretax Margin | -552,600.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -280,850.00% |
Dividends & Yields
Genomtec does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.02% |
| Shareholder Yield | -15.02% |
| Earnings Yield | -11.35% |
| FCF Yield | -5.64% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genomtec has an Altman Z-Score of 2.99. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.99 |
| Piotroski F-Score | n/a |